FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC

• 作者: Harm van Tinteren Houke M Klomp Koen J Hartemink Matthijs H van Gool Renato A Valdés Olmos Tjeerd S Aukema
• 来源期刊: 世界放射学杂志：英文版（电子版）
• 学科: 医学
• 关键词: NON-SMALL cell lung cancer EPIDERMAL growth factor receptor-tyrosine kinase inhibitors therapy Positron emission tomography-computed TOMOGRAPHY COMPUTED TOMOGRAPHY Response monitoring
• 年，卷（期）: 2014,（7）
• 页码范围: 392-398
• 页数: 7页
• 分类号: R734.2

摘要

Over recent years,[18F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography(FDG-PET/CT)has proven its role as a staging modality in patients with non-small cell lung cancer(NSCLC).The purpose of this review was to present the evidence to use FDG-PET/CT for response evaluation in patients with NSCLC,treated with epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitors(TKI).All published articles from 1November 2003 to 1 November 2013 reporting on 18FFDG-PET response evaluation during EGFR-TKI treatment in patients with NSCLC were collected.In total 7studies,including data of 210 patients were eligible for analyses.Our report shows that FDG-PET/CT responseduring EGFR-TKI therapy has potential in targeted treatment for NSCLC.FDG-PET/CT response is associated with clinical and radiologic response and with survival.Furthermore FDG-PET/CT response monitoring can be performed as early as 1-2 wk after initiation of EGFR-TKI treatment.Patients with substantial decrease of metabolic activity during EGFR-TKI treatment will probably benefit from continued treatment.If metabolic response does not occur within the first weeks of EGFR-TKI treatment,patients may be spared(further)unnecessary toxicity of ineffective treatment.Refining FDG-PET response criteria may help the clinician to decide on continuation or discontinuation of targeted treatment.